METHOD FOR SYNTHESIZING THIENO[3,2-B]PYRIDINE-5(4H)-ONE DERIVATIVE COMPOUND, USING GOLD CATALYST, AND USE THEREFOR

Abstract

Disclosed are a method for synthesizing a thieno[3,2-b]pyridine-5(4H)-one derivative by using a gold catalyst and a use of the derivative compound, wherein the novel thieno[3,2-b]pyridine-5(4H)-one derivative of the present disclosure, which is a compound synthesized using gold as a catalyst, has fluorescence characteristics with a wide range of emission wavelengths and thus can be helpfully used in various industrial fields, such as physics, chemistry, and biomedicine research.

Claims

1. A compound of chemical formula 1 below, an enantiomer or diastereomer thereof, or an acid or base addition salt thereof: ##STR00066## wherein, R.sub.1 is MeO or ##STR00067## and R.sub.2 is H, Me, ##STR00068##

2. The compound of claim 1, wherein the compound is selected from the group consisting of compounds having the structural formulas below: TABLE-US-00006 No Structural Formula  1  2  3  4  5  6  7  8  9 10 11 12 13

3. A method for preparing a compound of chemical formula 1 by the reaction scheme below using a gold catalyst: ##STR00082## wherein, R.sub.1 is MeO or ##STR00083## and R.sub.2 is H, Me, ##STR00084##

4. The method of claim 3, wherein the gold catalyst is any one selected from the group consisting of chloro(triphenylphosphine)gold(I), acetonitrile[(2-biphenyl)di-tert-butylphosphine]gold(I)hexafluoroantimonate, [bis(trifluoromethanesulfonyl)imidate](triphenylphosphine)gold(I), and chloro[1,3-bis(2,6-diisopropylphenyl)imidazole-2-ylidene]gold(I).

5. A fluorescent composition comprising, as an active ingredient, the compound of claim 1, an enantiomer or diastereomer thereof, or an acid or base addition salt thereof.

6. A kit for biomolecule labeling or analysis, the kit comprising the fluorescent composition of claim 5.

7. A composition for a pH sensor, the composition comprising, as an active ingredient, the compound of claim 1, an enantiomer or diastereomer thereof, or an acid or base addition salt thereof.

8. A pH sensor comprising the composition for a pH sensor of claim 7.

Description

DETAILED DESCRIPTION

[0023] The present disclosure is characterized by providing a novel thieno[3,2-b]pyridine-5(4H)-one derivative compound represented by the chemical formula below, an enantiomer or diastereomer thereof, or an acid or base addition salt thereof:

##STR00001##

[0024] wherein,

[0025] R.sub.1 is MeO or

##STR00002##

and

[0026] R.sub.2 is H, Me,

##STR00003##

[0027] The thieno[3,2-b]pyridine-5(4H)-one derivative compounds of the present disclosure were synthesized through a reaction using a gold catalyst, and an optimal type of gold catalyst for effectively synthesizing the derivative compounds exhibiting fluorescence at a high yield was selected.

[0028] The gold catalyst usable to synthesize the novel derivative compounds of the present disclosure may be, but is not limited to, any one selected from the group consisting of chloro(triphenylphosphine)gold(I), acetonitrile[(2-biphenyl)di-tert-butylphosphine]gold(I)hexafluoroantimonate, bis(trifluoromethanesulfonyl)imidate](triphenylphosphine)gold(I), and chloro[1,3-bis(2,6-diisopropylphenyl)imidazole-2-ylidene]gold(I), and may be preferably chloro[1,3-bis(2,6-diisopropylphenyl)imidazole-2-ylidene]gold(I).

[0029] As such, it was verified that the compounds of the present disclosure can be effectively obtained at a high yield by using a gold catalyst, even without the addition of Bronsted acids or vigorous reaction conditions.

[0030] In an embodiment of the present disclosure, specific structural formulas of the novel thieno[3,2-b]pyridine-5(4H)-one derivative compounds synthesized using a gold catalyst are shown in the following table.

TABLE-US-00001 No Structural Formula  1 [00004]  2 [00005]  3 [00006]  4 [00007]  5 [00008]  6 [00009]  7 [00010]  8 [00011]  9 [00012] 10 [00013] 11 [00014] 12 [00015] 13 [00016]

[0031] As used herein, the term “salt” encompasses pharmaceutically acceptable salts that are commonly used to form alkali metal salts of free acids and addition salts of free bases. The properties of salts are not matter so long as the salts are pharmaceutically acceptable. Suitable pharmaceutically acceptable acid addition salts can be prepared from inorganic or organic acids. Exemplary pharmaceutical salts are disclosed in the literature [Stahl, P. H., Wermuth, C. G., Eds. Handbook of Pharmaceutical Salts: Properties, Selection and Use; Verlag Helvetica Chimica Acta/Wiley-VCH: Zurich, 2002]. Specific non-limiting examples of the inorganic acids are hydrochloric acid, hydrobromic acid, hydroiodic acid, nitric acid, carbonic acid, sulfuric acid, and phosphoric acid. Suitable organic acids include, without limitation to, aliphatic, cycloaliphatic, aromatic, arylaliphatic, and heterocyclyl-containing carboxylic acids and sulfonic acids, for example, formic acid, acetic acid, propionic acid, succinic acid, glycolic acid, gluconic acid, lactic acid, malic acid, tartaric acid, citric acid, ascorbic acid, glucuronic acid, maleic acid, fumaric acid, pyruvic acid, aspartic acid, glutamic acid, benzoic acid, anthranilic acid, mesylic acid, stearic acid, salicylic acid, p-hydroxybenzoic acid, phenylacetic acid, mandelic acid, embonic acid (pamoic acid), methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, pantothenic acid, toluenesulfonic acid, 2-hydroxyethanesulfonic acid, sulfanilic acid, cyclohexylaminosulfonic acid, algenic acid, 3-hydroxybutyric acid, galactaric acid, or galacturonic acid. Suitable pharmaceutically acceptable salts of the free acid-containing compounds disclosed herein include, without limitation to, metal salts and organic salts. Exemplary metal salts include suitable alkali metal (Group Ia) salts, alkali earth metal (Group IIa) salts, and other physiologically acceptable metals, but are not limited thereto. Such salts may be prepared from aluminum, calcium, lithium, magnesium, potassium, sodium, and zinc. Exemplary organic salts may be prepared from primary amines, secondary amines, tertiary amines, and quaternary ammonium salts, for example, tromethamine, diethyl amine, tetra-N-methyl ammonium, N,N′-dibenzylethylene diamine, chloroprocaine, choline, diethanolamine, ethylene diamine, meglumine (N-methylglucamine), and procaine.

[0032] Structural, chemical, and stereochemical definitions are broadly taken from IUPAC recommendations, and more specifically from the glossary of terms used in [Physical Organic Chemistry (IUPAC Recommendations 1994) as summarized by Mueller, P. Pure Appl. Chem. 1994, 66, pp. 1077-1184 and Basic Terminology of Stereochemistry (IUPAC Recommendations 1996) as summarized by Moss, G. P. Pure Appl. Chem. 1996, 68, pp. 2193-2222].

[0033] Enantiomers are defined as one of a pair of molecular entities which are mirror images of each other and non-superimposable.

[0034] Diastereomers are defined as stereoisomers but not enantiomers. Diastereomers are stereoisomers not related as mirror images. Diastereomers are characterized by differences in physical properties, and by some differences in chemical behavior towards achiral as well as chiral reagents

[0035] The novel thieno[3,2-b]pyridine-5(4H)-one derivative compound represented by the above chemical formula provided in the present disclosure may be prepared by the following reaction scheme, and a specific preparation method is described in the following examples.

##STR00017##

[0036] In the reaction scheme,

[0037] R.sub.1 is MeO or

##STR00018##

and

[0038] R.sub.2 is H, Me,

##STR00019##

[0039] In addition, the present disclosure provides a fluorescent composition containing, as an active ingredient, the novel thieno[3,2-b]pyridine-5(4H)-one derivative compound of the present disclosure, an enantiomer or diastereomer thereof, or an acid or base addition salt thereof.

[0040] According to an embodiment of the present disclosure, as a result of conducting fluorescence characteristic analysis on the novel derivative compounds of the present disclosure, it was verified that these derivative compounds have an emission wavelength in a broad range from blue to green (dichloromethane solution) of 426-559 nm and blue to orange (acetonitrile solution) of 423-615 nm. Therefore, these derivative compounds can be used to have an emission wavelength selected from a range of blue to orange as needed.

[0041] In addition, the present disclosure can provide a kit for biomolecule labeling or analysis, the kit including the fluorescent composition of the present disclosure.

[0042] When the fluorescent composition of the present disclosure is used to label or analyze a biomolecule, the biomolecule may encompass all target molecules present in organisms. The novel derivative compounds of the present disclosure have high fluorescence characteristics and wide ranges of emission wavelengths and thus can detect and analyze the target molecules with more sensitivity and high accuracy.

[0043] The fluorescent composition of the present disclosure can also be used for dyeing biosamples, that is, cells, tissues, nucleic acids, and the like.

[0044] Further, the present disclosure can provide a composition for a pH sensor, the composition containing the novel derivative compound of the present disclosure, an enantiomer or diastereomer thereof, or an acid or base addition salt thereof, and can provide a pH sensor including the composition for a pH sensor.

[0045] According to an embodiment of the present disclosure, the derivative compounds were analyzed for fluorescence intensity in different pH ranges, respectively, and it was verified that each compound exhibited strong fluorescence intensity at a specific pH range. It can be therefore seen that each of the novel derivative compounds of the present disclosure can also be utilized as a sensor detecting a specific pH range.

[0046] Hereinafter, the present disclosure will be described in detail through examples. These examples are given for specifically illustrating the present disclosure, and the scope of the present disclosure is not limited thereto.

[0047] <Reagents and Instruments>

[0048] All anhydrous solvents, boronic acids, and other chemical reagents were purchased from Sigma Aldrich, Alfa Aesar and TCI. Methyl 3-amino-5-bromothiophene-2-carboxylate as a starting material was purchased from Matrix Scientific Co. The organic reactions were monitored by thin layer chromatography (TLC) with 0.25-mm pre-coated silica gel plates (Kieselgel 60F254). Flash column chromatography was performed on silica gel (70-230 mesh) using distilled organic solvents. All anhydrous solvents and other chemical reagents were purchased from Sigma Aldrich, Alfa Aesar and TCI. Methyl 3-amino-5-bromothiophene-2-carboxylate as a starting material was purchased from Matrix Scientific Co. The organic reactions were monitored by thin layer chromatography (TLC) with 0.25-mm pre-coated silica gel plates (Kieselgel 60F254), and flash column chromatography was performed on silica gel (70-230 mesh) using distilled organic solvents.

[0049] .sup.1H and .sup.13C spectra were recorded on Varian Unity-Inova 500 MHz and Bruker 600 MHz spectrometer. Chemical shifts are reported as δ (ppm) values relative to chloroform (CDCl.sub.3, δ 7.26) and dimethyl sulfoxide (DMSO-d6, δ 2.50), and the coupling constant was noted by Hz units. The molecular weights were measured by liquid chromatography-mass spectrometer (LC-MS) using ThermoRiningan spectrometer, and photophysical properties (UV-Vis spectra, emission, excitation, quantum yield, and molecular coefficient) were analyzed using Scinco 3000 spectrophotometer and a fluorometer (1 cm-quartz cell).

Example 1

Selection of Optimal Gold Catalyst for Synthesis of thieno[3,2-b]pyridine-5(4H)-one Derivative Compound

[0050] The present inventors conducted the following experiment to select an optimal gold catalyst as a gold catalyst for synthesis of a thieno[3,2-b]pyridine-5(4H)-one derivative compound.

[0051] First, gold catalysts shown in Table 1 below were used, and the yield of 4-methyl-2-phenylthieno[3,2-b]pyridin-5(4H)-one, which is a compound synthesized through Reaction Scheme 1 below, was analyzed. In addition, the reaction time used for each type of gold catalyst was differently set.

##STR00020##

TABLE-US-00002 TABLE 1 Type of gold catalyst, reaction time, and yield of synthesized compound (%) Time Yield No Au(I) of gold catalyst (h) (%) 1 Chloro(triphenylphosphine) gold(I) 18 28 2 (Acetonitrile) [(2-biphenyl)di-tert-butylphosphine] 18 46 gold(I) hexafluoroantimonate 3 [Bis(trifluoromethanesulfonyl)imidate] 18 58 (triphenylphosphine)gold(I)(2:1)toluene adduct 4 Chloro[1,3-bis(2,6-diisopropylphenyl)imidazol-2-ylidene]gold(I)  3 54 5 Chloro[1,3-bis(2,6-diisopropylphenyl))imidazol-2-ylidene]gold(I) 18 62 [00021][00022][00023][00024]

[0052] Specifically, the reaction of Reaction Scheme 1 above was conducted as follows. First, a N-methyl-N-(5-phenylthiophen-3-yl)propiolamide compound (mg, mmol, 1.0 equiv.) was dissolved in 1,4-dioxane, and a nitromethane solution in which each gold catalyst (mg, mmol, 0.10 equiv.) and silver hexafluoroantimonate (AgSbF.sub.6; mg, mmol, 0.10 equiv.) were solved was added thereto, followed by reaction at 70° C. for each time. After the completion of the reaction, water was added, and extraction was conducted three times using 5 ml of dichloromethane (DCM). Thereafter, the organic layer fraction was dried over Na.sub.2SO.sub.4, and evaporated in a vacuum state, thereby synthesizing 4-methyl-2-phenylthieno[3,2-b]pyridin-5(4H)-one. The type and reaction time of each metal catalyst used were as described in Table 1 above, and the yield of each reaction product was measured.

[0053] As a result, as shown in Table 1 above, 4-methyl-2-phenylthieno[3,2-b]pyridin-5(4H)-one was synthesized for all the four types of gold catalysts. It can be especially seen that, when the chloro[1,3-bis(2,6-diisopropylphenyl)imidazole-2-ylidene]gold(I) catalyst was used to perform the reaction for 18 hours, the reaction product was obtained at the highest yield.

Example 2

Synthesis of thieno[3,2-b]pyridine-5(4H)-one Derivative Compounds Using Gold Catalyst

<2-1> Synthesis of Substrate Compounds for Synthesis of Present Inventive thieno[3,2-b]pyridine-5(4H)-one Derivative Compounds

[0054] The present inventors selected the optimal gold catalyst for efficient synthesis of thieno[3,2-b]pyridine-5(4H)-one derivative compounds in Example 1 above, and further synthesized substrate compounds for synthesis of thieno[3,2-b]pyridine-5(4H)-one derivative compounds. The reaction for synthesis of substrate compounds is shown in Reaction Scheme 2 below, and the compounds, reaction conditions, and reaction product used in each reaction are shown in Table 2 below.

##STR00025##

TABLE-US-00003 TABLE 2 Time Yield No R.sub.1 R.sub.2 (h) (%) Reaction Product  1 4- methoxy- phenyl H  1 62 [00026]  2 4- methoxy- phenyl Me 68 30 [00027]  3 4- methoxy- phenyl Ph  2 50 [00028]  4 4- methoxy- phenyl 4- methoxy- phenyl  3 51 [00029]  5 4- methoxy- phenyl 4- cyanophenyl  1 50 [00030]  6 4- diethylamino- phenyl H  1 77 [00031]  7 4- diethylamino- phenyl Me 16 56 [00032]  8 4- diethylamino- phenyl Ph  0.5 74 [00033]  9 4- diethylamino- phenyl 4- methoxy- phenyl  3 83 [00034] 10 4- diethylamino- phenyl 4- methylester- phenyl  3 49 [00035] 11 4- diethylamino- phenyl 4- cyanophenyl  3 55 [00036] 12 4- diethylamino- phenyl 2- thiophene  0.5 68 [00037] 13 4- diethylamino- phenyl 2- pyridine  2 54 [00038]

[0055] Specifically, the reaction of Reaction Scheme 2 above was conducted as follows. A propiolic acid-based compound (157 μL, 2.547 mmol, 1.2 equiv.) and N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (EDC.HCl) (488.6 mg, 2.547 mmol, 1.2 equiv.) were added to a DMF solution (21 mL) in which a N-methyl-5-phenylthiophen-3-amine-based compound (400 mg, 2.124 mmol, 1.0 equiv) as a starting material in Reaction Scheme 2 above was dissolved, followed by reaction at 80° C. for each time. After the completion of the reaction, water was added. Thereafter, ethyl acetate (15 mL) was added to conduct extraction three times, and the organic layer fraction was dried over Na.sub.2SO.sub.4, and evaporated in a vacuum state, thereby synthesizing respective reaction products on Table 2. The starting material, reaction time, yield, and reaction product in each reaction are shown in Table 2 above.

<2-2> Synthesis of Present Inventive thieno[3,2-b]pyridine-5(4F1)-one Derivative Compounds Using Gold Catalyst

[0056] The reaction products synthesized in <2-1> above were used as starting materials, and the chloro[1,3-bis(2,6-diisopropylphenyl)imidazole-2-ylidene]gold(I) catalyst used in Example 1 above was used as a gold catalyst, and thieno[3,2-b]pyridine-5(4H)-one) derivative compounds were synthesized through Reaction Scheme 3 below. The present inventive thieno[3,2-b]pyridine-5(4H)-one) derivative compounds synthesized using the gold catalyst are shown in Table 3 below.

##STR00039##

[0057] Specifically, the reaction of Reaction Scheme 2 was conducted by the following method. First, the reaction products synthesized on Table 2 above were used as reaction starting materials of Reaction Scheme 3 above. In each reaction, a starting material compound (mg, mmol, 1.0 equiv.) was dissolved in 1,4-dioxane, and a nitromethane solution in which chloro[1,3-bis(2,6-diisopropylphenyl)imidazole-2-ylidene]gold(I)) (mg, mmol, 0.10 equiv.) as a gold catalyst and silver hexafluoroantimonate (AgSbF.sub.6; mg, mmol, 0.10 equiv.) were dissolved was added thereto, followed by reaction at 70° C. for each time (5 min, 15 min, 20 min, 30 min, 1 hr, 18 hr, and 24 hr). After the completion of the reaction, water was added, and 5 mL of dichloromethane (DCM) was used to conduct extraction three times. Thereafter, the organic layer fraction was dried over Na.sub.2SO.sub.4, and evaporated in a vacuum state, thereby synthesizing the present inventive thieno[3,2-b]pyridine-5(4H)-one derivative compounds. The structure formula, reaction time, and yield of each of the synthesized compounds are shown in Table 3, and each of the synthesized compounds was purified on silica by flash column chromatography (hexane/EtOAc=1/1, v/v), and then subjected to NMR analysis.

TABLE-US-00004 TABLE 3 Reaction No Chemical Formula Starting material (Reaction product on Table 2 above) time Yield  1 [00040] [00041] 15 min 39%  2 [00042] [00043]  5 min 77%  3 [00044] [00045] 15 min 65%  4 [00046] [00047] 30 min 93%  5 [00048] [00049]  5 min 93%  6 [00050] [00051] 15 min 74%  7 [00052] [00053] 20 min 92%  8 [00054] [00055] 18 hr  56%  9 [00056] [00057] 30 min 81% 10 [00058] [00059] 30 min 81% 11 [00060] [00061] 30 min 73% 12 [00062] [00063] 30 min 83% 13 [00064] [00065] 24 hr  40%

<2-3> NMR Analysis of Present Inventive thieno[3,2-b]pyridine-5(4H)-one Derivative Compounds Synthesized Using Gold Catalyst

[0058] The chemical formula names and NMR analysis results of the thieno[3,2-b]pyridine-5(4H)-one derivative compounds synthesized by the present inventive methods shown in Table 3 are as follows.

[0059] (1) NMR Analysis Results of Chemical Formula 1 on Table 3

[0060] As a result of NMR analysis of Chemical Formula 1 on Table 3, the chemical formula is named as 2-(4-methoxyphenyl)-4-methylthieno[3,2-b]pyridin-5(4H)-one. .sup.1H NMR (600 MHz, CDCl.sub.3) δ 7.63 (d, J=9.0 Hz, 1H), 7.59 (d, J=8.4 Hz, 2H), 7.13 (s, 1H), 6.96 (d, J=9.0 Hz, 2H), 6.54 (d, J=9.0 Hz, 1H), 3.86 (s, 3H), 3.74 (s, 3H); .sup.13C NMR (150 MHz, CDCl.sub.3) δ162.4, 160.6, 148.8, 145.1, 133.0, 127.6, 126.1, 117.2, 116.7, 114.7, 110.9, 55.6, 31.9; LRMS (APCI): m/z calcd for C.sub.15H.sub.14NO.sub.2S[M+H].sup.+272.07. found 272.20.

[0061] (2) NMR Analysis Results of Chemical Formula 2 on Table 3

[0062] As a result of NMR analysis of Chemical Formula 2 on Table 3, the chemical formula is named as 2-(4-methoxyphenyl)-4,7-dimethylthieno[3,2-b]pyridin-5(4H)-one. .sup.1H NMR (600 MHz, CDCl.sub.3) δ 7.59 (d, J=8.4 Hz, 2H), 7.13 (s, 1H), 6.95 (d, J=8.4 Hz, 2H), 6.38 (s, 1H), 3.86 (s, 3H), 3.70 (s, 3H), 2.36 (s, 3H); .sup.13C NMR (150 MHz, CDCl.sub.3) δ162.9, 160.5, 147.6, 144.0, 144.0, 127.5, 126.2, 119.4, 115.6, 114.7, 111.2, 55.6, 31.8, 19.9; LRMS (APCI): m/z calcd for C.sub.16H.sub.16NO.sub.2S[M+H].sup.+286.09. found 286.20.

[0063] (3) NMR Analysis Results of Chemical Formula 3 on Table 3

[0064] As a result of NMR analysis of Chemical Formula 3 on Table 3, the chemical formula is named as 2-(4-methoxyphenyl)-4-methyl-7-phenylthieno[3,2-b]pyridin-5(4H)-one. .sup.1H NMR (600 MHz, CDCl.sub.3) δ 7.68 (dd, J=7.5 Hz and J=2.1 Hz, 2H), 7.58 (d, J=8.4 Hz, 2H), 7.53-7.49 (m, 3H), 7.20 (s, 1H), 6.94 (d, J=8.4 Hz, 2H), 6.61 (s, 1H), 3.85 (s, 3H), 3.78 (s, 3H); .sup.13C NMR (150 MHz, CDCl.sub.3) δ162.9, 160.6, 148.9, 147.2, 145.0, 137.5, 129.7, 129.1, 127.8, 127.5, 126.0, 117.5, 114.8, 114.7, 111.2, 55.6, 32.0; LRMS (APCI): m/z calcd for C.sub.21H.sub.18NO.sub.2S[M+H].sup.+348.10. found 348.20.

[0065] (4) NMR Analysis Results of Chemical Formula 4 on Table 3

[0066] As a result of NMR analysis of Chemical Formula 4 on Table 3, the chemical formula is named as 2,7-bis(4-methoxyphenyl)-4-methylthieno[3,2-b]pyridin-5(4H)-one. .sup.1H NMR (600 MHz, CDCl.sub.3) δ 7.64 (d, J=8.4 Hz, 2H), 7.59 (d, J=8.4 Hz, 2H), 7.19 (s, 1H), 7.03 (d, J=8.4 Hz, 2H), 6.94 (d, J=8.4 Hz, 2H), 6.56 (s, 3H), 3.88 (s, 3H), 3.85 (s, 3H), 3.77 (s, 3H); .sup.13C NMR (150 MHz, CDCl.sub.3) δ163.0, 160.9, 160.6, 148.6, 146.7, 144.9, 129.8, 129.1, 127.5, 126.1, 117.5, 114.7, 114.5, 114.3, 111.2, 55.6, 55.5, 31.9; LRMS (APCI): m/z calcd for C.sub.22H.sub.20NO.sub.3S[M+H].sup.+378.12. found 378.10.

[0067] (5) NMR Analysis Results of Chemical Formula 5 on Table 3

[0068] As a result of NMR analysis of Chemical Formula 5 on Table 3, the chemical formula is named as 4-(2-(4-methoxyphenyl)-4-methyl-5-oxo-4,5-dihydrothieno[3,2-b]pyridin-7-yl)benzonitrile. .sup.1H NMR (600 MHz, CDCl.sub.3) δ 7.83-7.78 (m, 4H), 7.59 (d, J=9.0 Hz, 2H), 7.24 (s, 1H), 6.96 (d, J=8.4 Hz, 2H), 6.58 (s, 1H), 3.86 (s, 3H), 3.79 (s, 3H); .sup.13C NMR (150 MHz, CDCl.sub.3) δ162.5, 160.9, 149.3, 145.5, 145.1, 141.9, 133.0, 128.5, 127.6, 125.7, 118.4, 116.2, 115.5, 114.8, 113.5, 111.3, 55.6, 32.1; LRMS (APCI): m/z calcd for C.sub.22H.sub.17N.sub.2O.sub.2S[M+H].sup.+373.10. found 373.10.

[0069] (6) NMR Analysis Results of Chemical Formula 6 on Table 3

[0070] As a result of NMR analysis of Chemical Formula 6 on Table 3, the chemical formula is named as 2-(4-(diethylamino)phenyl)-4-methylthieno[3,2-b]pyridin-5(4H)-one. .sup.1H NMR (500 MHz, CDCl.sub.3) δ 7.44 (dd, J=6.5 Hz and J=2.3 Hz, 2H), 6.70-6.67 (m, 3H), 5.81 (d, J=1.5 Hz, 1H), 3.62 (br s, 1H), 3.39 (q, J=7.0 Hz, 4H), 2.84 (s, 3H), 1.20 (t, J=7.3 Hz, 6H); .sup.13C NMR (125 MHz, CDCl.sub.3) δ150.2, 147.3, 144.6, 126.8, 122.1, 113.7, 111.7, 92.6, 44.5, 32.7, 12.8; LRMS (APCI): m/z calcd for C.sub.18H.sub.21N.sub.2OS[M+H]+313.14. found 313.20.

[0071] (7) NMR Analysis Results of Chemical Formula 7 on Table 3

[0072] As a result of NMR analysis of Chemical Formula 7 on Table 3, the chemical formula is named as 2-(4-(diethylamino)phenyl)-4,7-dimethylthieno[3,2-b]pyridin-5(4H)-one. .sup.1H NMR (600 MHz, CDCl.sub.3) δ 7.50 (d, J=8.4 Hz, 2H), 7.02 (s, 1H), 6.68 (d, J=8.4 Hz, 2H), 6.31 (s, 1H), 3.68 (s, 3H), 3.40 (q, J=10.8 Hz, 4H), 2.33 (s, 3H), 1.20 (t, J=7.2 Hz, 3H); .sup.13C NMR (150 MHz, CDCl.sub.3) δ162.9, 149.0, 148.3, 144.3, 144.0, 127.4, 120.3, 118.2, 114.6, 111.7, 109.2, 44.6, 31.8, 19.8, 12.7; LRMS (APCI): m/z calcd for C.sub.19H.sub.23N.sub.2OS[M+H].sup.+327.15. found 327.10.

[0073] (8) NMR Analysis Results of Chemical Formula 8 on Table 3

[0074] As a result of NMR analysis of Chemical Formula 8 on Table 3, the chemical formula is named as 2-(4-(diethylamino)phenyl)-4-methyl-7-phenylthieno[3,2-b]pyridin-5(4H)-one. .sup.1H NMR (600 MHz, CDCl.sub.3) δ 7.68 (d, J=7.2 Hz, 2H), 7.52-7.46 (m, 5H), 7.11 (s, 1H), 6.67 (d, J=8.4 Hz, 2H), 6.55 (s, 1H), 3.77 (s, 3H), 3.40 (q, J=7.0 Hz, 4H), 1.19 (t, J=7.2 Hz, 3H); .sup.13C NMR (150 MHz, CDCl.sub.3) δ163.0, 150.3, 148.5, 147.1, 145.4, 137.7, 129.6, 129.0, 127.8, 127.4, 120.2, 116.3, 113.8, 111.7, 109.2, 44.6, 31.9, 12.7; LRMS (APCI): m/z calcd for C.sub.24H.sub.25N.sub.2OS[M+H].sup.+389.17. found 389.20.

[0075] (9) NMR Analysis Results of Chemical Formula 9 on Table 3

[0076] As a result of NMR analysis of Chemical Formula 9 on Table 3, the chemical formula is named as 2-(4-(diethylamino)phenyl)-7-(4-methoxyphenyl)-4-methylthieno[3,2-b]pyridin-5(4H)-one. .sup.1H NMR (600 MHz, CDCl.sub.3) δ 7.64 (d, J=8.4 Hz, 2H), 7.51 (d, J=8.4 Hz, 2H), 7.10 (s, 1H), 7.02 (d, J=8.4 Hz, 2H), 6.67 (d, J=8.4 Hz, 2H), 6.51 (s, 1H), 3.88 (s, 3H), 3.76 (s, 3H), 3.40 (q, J=7.2 Hz, 4H), 1.19 (t, J=6.9 Hz, 3H); .sup.13C NMR (150 MHz, CDCl.sub.3) δ163.0, 160.7, 150.1, 148.5, 146.7, 145.3, 130.1, 129.1, 127.4, 120.3, 116.4, 114.5, 113.3, 111.7, 109.2, 55.5, 44.6, 31.9, 12.7; LRMS (APCI): m/z calcd for C.sub.25H.sub.27N.sub.2O.sub.2S[M+H].sup.+419.18. found 418.90.

[0077] (10) NMR Analysis Results of Chemical Formula 10 on Table 3

[0078] As a result of NMR analysis of Chemical Formula 10 on Table 3, the chemical formula is named as methyl 4-(2-(4-(diethylamino)phenyl)-4-methyl-5-oxo-4,5-dihydrothieno[3,2-b]pyridin-7-yl)benzoate. .sup.1H NMR (600 MHz, CDCl.sub.3) δ 8.17 (d, J=8.4 Hz, 2H), 7.75 (d, J=8.4 Hz, 2H), 7.50 (d, J=9.0 Hz, 2H), 7.12 (s, 1H), 6.67 (d, J=9.0 Hz, 2H), 6.55 (s, 1H), 3.96 (s, 3H), 3.78 (s, 3H), 3.40 (q, J=7.2 Hz, 4H), 1.20 (t, J=6.9 Hz, 3H); .sup.13C NMR (150 MHz, CDCl.sub.3) δ166.7, 162.8, 150.6, 148.6, 146.0, 145.6, 142.1, 131.1, 130.4, 127.9, 127.5, 120.0, 115.7, 114.2, 111.7, 109.2, 52.5, 44.6, 32.0, 12.7; LRMS (APCI): m/z calcd for C.sub.26H.sub.27N.sub.2O.sub.3S[M−H].sup.−447.17. found 445.0.

[0079] (11) NMR Analysis Results of Chemical Formula 11 on Table 3

[0080] As a result of NMR analysis of Chemical Formula 11 on Table 3, the chemical formula is named as 4-(2-(4-(diethylamino)phenyl)-4-methyl-5-oxo-4,5-dihydrothieno[3,2-b]pyridin-7-yl)benzonitrile. .sup.1H NMR (600 MHz, CDCl.sub.3) δ 7.81-7.77 (m, 4H), 7.50 (d, J=8.4 Hz, 2H), 7.12 (s, 1H), 6.67 (d, J=8.4 Hz, 2H), 6.51 (s, 1H), 3.77 (s, 3H), 3.41 (q, J=7.0 Hz, 4H), 1.20 (t, J=7.2 Hz, 3H); .sup.13C NMR (150 MHz, CDCl.sub.3) δ162.6, 150.9, 148.7, 145.9, 145.0, 142.2, 132.9, 128.6, 127.5, 119.7, 118.5, 115.1, 114.3, 113.3, 111.6, 109.2, 44.6, 32.0, 12.7; LRMS (APCI): m/z calcd for C.sub.25H.sub.24N.sub.3OS[M+H].sup.+414.16. found 413.90.

[0081] (12) NMR Analysis Results of Chemical Formula 12 on Table 3

[0082] As a result of NMR analysis of Chemical Formula 12 on Table 3, the chemical formula is named as 2-(4-(diethylamino)phenyl)-4-methyl-7-(thiophen-2-yl)thieno[3,2-b]pyridin-5(4H)-one. .sup.1H NMR (600 MHz, CDCl.sub.3) δ 7.66 (d, J=3.6 Hz, 1H), 7.53 (d, J=8.4 Hz, 2H), 7.47 (d, J=5.4 Hz, 1H), 7.18 (t, J=4.5 Hz, 1H), 7.09 (s, 1H), 6.71 (s, 1H), 6.68 (d, J=8.4 Hz, 2H), 3.75 (s, 3H), 3.41 (q, J=7.2 Hz, 4H), 1.20 (t, J=6.9 Hz, 3H); .sup.13C NMR (150 MHz, CDCl.sub.3) δ162.6, 150.2, 148.6, 145.7, 139.5, 139.4, 128.2, 127.7, 127.54, 127.50, 120.0, 114.9, 112.6, 111.7, 109.2, 44.6, 31.9, 12.7; LRMS (APCI): m/z calcd for C.sub.22H.sub.23N.sub.2OS.sub.2[M+H].sup.+395.13. found 395.20.

[0083] (13) NMR Analysis Results of Chemical Formula 13 on Table 3

[0084] As a result of NMR analysis of Chemical Formula 13 on Table 3, the chemical formula is named as 2-(4-(diethylamino)phenyl)-4-methyl-7-(pyridin-2-yl)thieno[3,2-b]pyridin-5(4H)-one. .sup.1H NMR (600 MHz, CDCl.sub.3) δ 7.66 (d, J=3.6 Hz, 1H), 7.53 (d, J=8.4 Hz, 2H), 7.47 (d, J=5.4 Hz, 1H), 7.18 (t, J=4.5 Hz, 1H), 7.09 (s, 1H), 6.71 (s, 1H), 6.68 (d, J=8.4 Hz, 2H), 3.75 (s, 3H), 3.41 (q, J=7.2 Hz, 4H), 1.20 (t, J=6.9 Hz, 3H); .sup.13C NMR (150 MHz, CDCl.sub.3) δ162.6, 150.2, 148.6, 145.7, 139.5, 139.4, 128.2, 127.7, 127.54, 127.50, 120.0, 114.9, 112.6, 111.7, 109.2, 440.6, 31.9, 12.7; LRMS (APCI): m/z calcd for C.sub.23H.sub.24N.sub.3OS[M+H].sup.+390.16. found 389.95.

Example 3

[0085] Characterization of Fluorophores of Present Novel Derivative Compounds

[0086] The present novel derivative compounds synthesized in Example 2 above were subjected to photophysical analysis, and the results are shown in Table 4 below.

TABLE-US-00005 TABLE 4 in dichloromethane (10 μM) in acetonitrile (10 μM) Derivative Stoke's Stoke's Compound λ.sub.abs λ  Brightness shift λ.sub.abs λ  Brightness shift 1 370 426 24,000 0.79 19,100 56 370 423 10,700 0.47  5,000 53 2 370 426 27,600 0.99 27,300 56 365 424 25,800 0.78 20,100 59 3 378 22,600 0.56 12,700 58 376 435 26,500 0.42 11,100 59 4 377 435 29,000  9,000 58 376 433 18,800 0.25  4,700 57 5 384 474 22,400 0.70 15,700 90 382 482 13,800 0.78 10,800 100 6 400 469 16,400 0.86 14,100 69 396 482 17,800 0.81 14,400 86 7 398 467 31,100 0.97 30,200 69 395 478 47,100 0.94 44,300 83 8 408 491 81,400 0.98 79,800 83 407 516 84,200 0.80 67,400 109 9 404 484 28,700 0.98 28,100 80 404 504 48,100 0.99 47,600 100 10 418 544 0.70 13,900 126  417 599 44,500 0.03  1,300 182 11 422 559 29,000 0.92 20,300 137  418 615 31,600 0.04  1,300 197 12 420 516 29,000 0.92 26,700 96 420 41,000 0.89 36,500 126 13 412 532 10,400 0.75 10,400 406  406 572 10,400 0.44  4,600 166 indicates data missing or illegible when filed

[0087] It can be seen from the analysis results that the compounds of the present disclosure on Table 4 above showed a wide range of fluorescence emission (λem: 426-559 nm, λem: 423-615 nm) with large Stokes shifts (up to 137 nm in dichloromethane and up to 197 nm in acetonitrile) and high quantum yields (up to 99% in dichloromethane and up to 99% in acetonitrile). For reference, the Stokes shift refers to a difference between the maximum value at the first absorption and the maximum value of the fluorescence spectrum, and the Stokes shift can provide information on excited states. For example, when the dipole moment of the fluorophore is higher than that in the ground state, the Stokes shift increases in proportion to the polarity of a solvent, and this feature can be utilized in a probe for fluorescence polarization.

[0088] Therefore, it can be seen that the novel derivative compounds synthesized using a gold catalyst can be used for physics, chemistry, and biomedicine research, and especially, the derivative compounds have a wide range of emission wavelength and thus derivative compounds having a selective range of emission wavelength can be selected and used as needed.

[0089] As set forth above, the present disclosure has been described with reference to preferable embodiments. A person skilled in the art to which the present disclosure pertain would understand that the present disclosure could be implemented in a modified form without departing from the inherent characteristics of the present disclosure. Accordingly, the embodiments described herein should be considered from an illustrative aspect rather than from a restrictive aspect. The scope of the present disclosure should be defined not by the detailed description but by the appended claims, and all differences falling within a scope equivalent to the claims should be construed as being included in the present disclosure.